CBC Group continues to expand its global healthcare ecosystem to fulfil unmet medical needs
Hasten fast-tracks transformative medicines for patients in China
Hasten Biopharmaceutic Co., Ltd today announced that it has acquired a portfolio of five prescription pharmaceutical products sold in China from Takeda Pharmaceutical Company Limited. Hasten is funded by CBC Group ("CBC"), Asia's largest healthcare-dedicated investment firm, Hefei Industry Investment Group, and Feidong County of Hefei City.
Under the terms of the acquisition, Hasten will acquire the Chinese Mainland-exclusive rights of Ebrantil
